Figure S1-S7 from Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non–Small Cell Lung Cancer Cells

Autor: Shinichi Toyooka, Shuta Tomida, Junichi Soh, Hiromasa Yamamoto, Yusuke Ogoshi, Eisuke Kurihara, Tatsuaki Takeda, Takahiro Yoshioka, Hiroki Sato, Hidejiro Torigoe, Yuta Takahashi, Kazuhiko Shien, Kei Namba
Rok vydání: 2023
DOI: 10.1158/1541-7786.22514668
Popis: Figure S1. Copy numbers of YES1 in osimertinib-resistant cell lines. Figure S2. PARP and MET expressions in MET-amplified osimertinib-resistant cell lines. Figure S3. Relative ALDH1A1 and ABCB1 expression levels using qRT-PCR in NSCLC EGFR-mutant cell lines and their corresponding osimertinib-resistant cell lines. Figure S4. Expressions of AXL protein in NSCLC EGFR-mutant cell lines and their corresponding osimertinib-resistant cell lines. Figure S5. Copy numbers of AXL in osimertinib-resistant cell lines. Figure S6. siRNA and combined drug treatment studies in HCC4006 and HCC4006 resistant cells. Figure S7. Combined treatment with AXL knockdown and osimertinib in H1975 and H1975 resistant cells.
Databáze: OpenAIRE